VERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

Questions around this news

What kinds of therapies are in VERAXA’s oncology pipeline?
The company describes a pipeline that includes conditionally active T-cell engagers, bispecific antibody-drug conjugates, and other engineered antibody therapeutics. It says it is advancing its lead oncology programs toward clinical development and that regulatory feedback from Germany’s Paul-Ehrlich-Institute provided additional clarity for development of its lead T-cell engager program.
How does a T-cell engager work?
A T-cell engager is designed to bind both a target on a cancer cell and a target on a T cell, an immune cell. By bringing the cells into proximity, the treatment can help direct the T cell to recognize and attack the cancer cell. The exact targets and design vary among therapies.
What is a bispecific antibody-drug conjugate?
A bispecific antibody-drug conjugate combines an antibody designed to bind two different targets with a linked drug payload. The antibody component can help guide the payload toward cells displaying relevant targets. The structure and intended use of these medicines vary, and the term alone does not establish how a particular candidate performs.

The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer.
The leadership change comes as the company advances its proprietary BiTAC(R) technology platform toward clinical development.
VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics.
Recent regulatory feedback from Germany’s Paul-Ehrlich-Institute has provided additional clarity for development of the company’s lead BiTAC(R)-TCE program.
Investors are watching companies developing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics researcher Christoph Erkel, Ph.D., as Chief Scientific Officer, reinforcing the company’s focus on advancing its proprietary BiTAC(R) technology platform as it prepares its lead oncology programs for clinical development. The announcement comes at a time when the biotechnology company is moving several elements of its research pipeline forward while expanding its scientific and regulatory capabilities.

According to the company, Dr. Erkel previously served as Vice President of Research & Development, where he helped oversee development of VERAXA’s antibody therapeutics portfolio. In his new role, he will lead scientific strategy across the company’s BiTAC(R) platforms and broader oncology pipeline while directing efforts to accelerate product candidates toward…

At a glance

Company: VERAXA Biotech
Ticker: NASDAQ: VRXA
Announcement: Executive

People

Dr. Christoph ErkelChief Scientific Officer

Products and programs

BiTAC technology platform
BiTAC-TCE program
Conditionally active T-cell engagers
Bispecific ADCs
Engineered antibody therapeutics

SEC filings

Earlier from VERAXA Biotech

Back to News Center